What is the diagnosis and treatment for Rozarem?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 16, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Rozarem (Ramelteon): Medication Overview

Rozarem (ramelteon) is a melatonin receptor agonist approved for treating insomnia characterized by difficulty with sleep onset, administered as 8 mg orally 30 minutes before bedtime, and is not classified as a controlled substance. 1

Indication and Diagnosis

Rozarem is indicated for patients with chronic insomnia who specifically have difficulty initiating sleep (prolonged sleep latency). 1 The diagnosis of insomnia requiring treatment should be based on:

  • Persistent difficulty falling asleep (prolonged sleep onset latency)
  • Duration of symptoms consistent with chronic insomnia
  • Impact on daytime functioning or quality of life 1

Treatment Regimen

Standard Dosing

  • 8 mg orally administered 30 minutes before bedtime 1
  • Treatment can be continued long-term, as studies demonstrate maintained efficacy through 6 months 1
  • No dose tapering required upon discontinuation, as ramelteon is not associated with withdrawal symptoms or rebound insomnia 1

Clinical Efficacy

Objective Sleep Parameters

  • Latency to persistent sleep (LPS) improves at week 1 and maintains throughout 5-week and 6-month studies 1
  • Total sleep time (TST) and sleep efficiency (SE) show improvement primarily during the first week of treatment 1

Subjective Sleep Parameters

  • Subjective sleep latency (sSL) improvements are inconsistent across studies 1
  • When sSL improvement occurs at week 1, effects maintain through 5-week studies but not consistently through 6-month studies 1

Safety Profile

Favorable Safety Characteristics

  • Well tolerated with minimal adverse effects 1
  • No impairment of next-day cognitive or motor performance 1
  • No withdrawal symptoms upon discontinuation 1
  • No rebound insomnia after stopping treatment 1
  • No abuse potential - not classified as a controlled substance 1

Overdose Management

  • In reported ramelteon ingestions to Texas poison centers (2005-2009), 88.3% resulted in no significant clinical effect 2
  • 75% of single-agent ramelteon ingestions were managed at healthcare facilities, but outcomes were generally benign 2
  • Standard supportive care is adequate for overdose management 2

Important Clinical Considerations

Patient Selection

  • Ideal for patients with sleep-onset insomnia rather than sleep maintenance problems 1
  • Appropriate for patients requiring long-term therapy due to favorable safety profile 1
  • Suitable for patients with substance abuse concerns given lack of controlled substance classification 1

Limitations

  • Inconsistent improvements in subjective sleep measures across all patients 1
  • Primary benefit in first week for total sleep time and sleep efficiency, with less consistent long-term effects on these parameters 1

Delirium Prevention (Off-Label Use)

Ramelteon is NOT recommended for delirium prevention in hospitalized patients, as meta-analysis of randomized controlled trials (n=443) showed no reduction in incident delirium risk (OR=0.49,95% CI=0.13-1.85). 3

References

2
Research

Ramelteon ingestions reported to Texas poison centers, 2005-2009.

The Journal of emergency medicine, 2012

Related Questions

What are the doses in milligrams (mg) for 100% and 90% of a medication, given that 5.8 mg is equivalent to 10% of the dose?
What medication options are available for a patient with PTSD and insomnia, currently on sertraline 100mg daily, with inadequate sleep response to trazodone and doxepin?
What is the equivalent dosage of Xarelto (rivaroxaban) for a patient on Pradaxa (dabigatran) 150 mg twice daily (bid) for stroke prevention in atrial fibrillation?
What happens if I take 75mg of medication instead of the prescribed 7.5mg?
What are the implications of administering a medication at a rate of 1 milligram (mg) per minute for one hour?
What is the comparison between teriparatide (recombinant human parathyroid hormone) and romosuzumab (monoclonal antibody) for osteoporosis treatment?
Is P2Y12 (P2Y12 receptor) inhibitor therapy required in patients with stress-induced cardiomyopathy and evidence of troponin leak?
What is a recommended antiemetic if Zofran (ondansetron) is not effective?
What is the initial step in the workup of a patient with normocytic anemia?
What is the recommended treatment for a candidiasis (fungal infection) urinary tract infection (UTI)?
What is the recommended treatment for chemosis with loteprednol (loteprednol etabonate)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question